Extended Data Fig. 2: Validation of in vivo cellular FDG uptake assay.

a, Intravenous (IV) anti-CD45 PE staining of leukocytes from designated tissues gated on live CD45⁺ cells. b, Demonstration of dynamic range of ¹⁸F quantification using serially diluted in vivo FDG-labelled splenocytes. c, Correlation plots of CPM per million live cells versus cell viability, cells counted and tumour mass across multiple tumour cell populations. Only the CD45⁻ and other CD45⁺ simple linear regressions had slopes significantly different than 0 for tumour mass (n = 10 mice). d, FDG-labelled digest supernatant from in vivo labelled MC38 tumours was applied to FDG-naive MC38 tumour single-cell suspensions to determine the contribution of ex vivo background FDG uptake to the final signal. e, Cellular FDG avidity in designated ex vivo and in vivo labelled MC38 tumour cell populations (n = 4 mice/group). f, Cellular FDG avidity in designated tumour cell fractions from MC38 THY1.1 tumours (n = 2 mice). g, Proportion of CD45⁺ and THY1.1⁺ cells, cell viability and live-cell yield from MC38 THY1.1 tumours (n = 2 mice for tumours; n = 5 mice for spleens). h, Representative flow cytometry analysis of MC38 THY1.1 tumour fractions. Each data point represents a biological replicate; data are mean ± s.e.m. Data in b, d–h are from a representative study performed independently at least twice.

Source data